文献速递特殊人群用药治疗药物监测与药物基因组学药物不良反应与药物警戒

格列本脲治疗妊娠期糖尿病时CYP2C9与OATP1B3基因变异与低血糖及血糖控制的关系

Hypoglycemia and Glycemic Control With Glyburide in Women With Gestational Diabetes and Genetic Variants of Cytochrome P450 2C9 and/or OATP1B3.
PubMed 文献 · Clin Pharmacol Ther · 2021-02-09

本研究为INDAO试验的辅助研究,纳入117例接受格列本脲治疗的妊娠期糖尿病孕妇,评估CYP2C9和OATP1B3基因多态性联合对低血糖和血糖控制的影响。结果显示,治疗第2周变异基因组低血糖风险显著高于中间组和野生型组(20.0% vs 8.1% vs 4.1%,P=0.03),且变异基因组妊娠期格列本脲末次每日剂量更低(4.7 mg vs 8.7 mg vs 5.7 mg,P<0.01)。

要点

  • CYP2C9*3和OATP1B3*4功能缺失变异与格列本脲治疗妊娠期糖尿病时低血糖风险升高相关。
  • 变异基因组低血糖风险在治疗第2周为20.0%,显著高于中间组8.1%和野生型组4.1%。
  • 变异基因组妊娠期格列本脲末次每日剂量更低(4.7 mg vs 野生型8.7 mg,P<0.01)。

核心结论

  • CYP2C9*3和OATP1B3*4功能缺失变异与妊娠期糖尿病妇女接受格列本脲治疗时更高的低血糖风险和更低的格列本脲剂量相关,与CYP2C9和OATP1B3的药代动力学作用一致。

研究设计与样本

  • INDAO试验的辅助研究,纳入117例接受格列本脲治疗的妊娠期糖尿病孕妇。
  • 按基因型分为三组:野生型基因组(CYP2C9*1和OATP1B3*1(699G)均为野生型等位基因)、中间组(CYP2C9*2等位基因携带者或OATP1B3*4(699G>A)杂合子)、变异基因组(CYP2C9*3等位基因携带者和/或OATP1B3*4(699G>A)纯合变异)。

主要发现

  • 治疗第2周低血糖风险在变异基因组为20.0%(4/20),中间组为8.1%(3/37),野生型基因组为4.1%(2/49),P=0.03。
  • 妊娠期格列本脲末次每日剂量在变异基因组为4.7 mg(SD 3.5),野生型组为8.7 mg(SD 5.7),中间组为5.7 mg(SD 3.7),P<0.01。

临床怎么用

  • 对接受格列本脲治疗的妊娠期糖尿病孕妇,可考虑CYP2C9和OATP1B3基因型检测以评估低血糖风险并指导剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glyburide is mainly metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme and enters the liver via the transporter OATP1B3. The variants OATP1B3*4 (699 G>A; rs7311358) and CYP2C9*2 and *3 are known to have a significant influence on the hepatic uptake and metabolism of glyburide, with lower clearance than in the wild type. In an ancillary study of the INDAO trial, we selected 117 pregnant women with gestational diabetes treated by glyburide and assessed the role of the combined CYP2C9 and OATP1B3 genetic polymorphisms in hypoglycemia and glycemic control. Three groups were constituted: (1) the wild-type genotype group (wild-type allele genotype for both CYP2C9*1 and OATP1B3*1 (699G)), (2) the intermediate group (carriers of CYP2C9*2 allele or OATP1B3*4 (699G>A) heterozygous), and (3) the variant group (carriers of CYP2C9*3 allele and/or OATP1B3*4 (699G>A) homozygous variant). We found that the risk of hypoglycemia was significantly higher in the variant genotype at the second week of treatment: 20.0% (4/20) vs. 8.1% (3/37) in the intermediate group and 4.1% (2/49) in the wild-type genotype group (P = 0.03). The last daily dose of glyburide during pregnancy was lower for patients in the variant genotype group: 4.7 mg (SD 3.5) vs. 8.7 mg (SD 5.7) in the wild-type group and 5.7 mg (SD 3.7) in the intermediate group (P < 0.01). In conclusion, the no-function variants CYP2C9*3 and OATP1B3*4 are associated with a higher risk of hypoglycemia and a lower dose of glyburide in women with gestational diabetes treated with glyburide, which is consistent with the pharmacokinetic roles of both CYP2C9 and OATP1B3.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bouchghoul H, Bouyer J, Senat MV, et al. Hypoglycemia and Glycemic Control With Glyburide in Women With Gestational Diabetes and Genetic Variants of Cytochrome P450 2C9 and/or OATP1B3. Clin Pharmacol Ther. 2021. PMID: 33341937. doi:10.1002/cpt.2142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。